Acadia Pharmaceuticals | ACAD - Pre Tax Profit


Acadia Pharmaceuticals reported $46.47M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Eisai JPY 25.28B 33.22B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
J&J USD 8.66B 839M Jun/2026
Moderna USD -1.33B 535M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Prothena USD 32.72M 54.3M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026